Anuncio • Jul 31
InspireMD, Inc. Appoints Kathleen Kennedy as Senior Vice President of Global Sales and Marketing InspireMD, Inc. announced the appointment of accomplished commercial leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing, reporting to CEO Marvin Slosman. Ms. Kennedy brought more than 30 years of medical device sales leadership experience, including significant expertise in carotid intervention and carotid stenting. Having previously led regional sales efforts supporting the U.S. launch of CGuard Prime, she returned to InspireMD with deep relationships across the vascular, neurovascular and cardiovascular physician communities, as well as extensive experience working with health systems that are key to driving adoption of carotid therapies. Throughout her career, Ms. Kennedy held commercial leadership positions in cardiovascular, vascular and neurovascular medical technologies, building extensive experience in physician engagement, market development, and sales execution. Ms. Kennedy re-joined InspireMD from Omniscient Neurotechnology, where she served briefly as Vice President of Sales for North America. Prior to that, she served as Sales Director at InspireMD, as Senior Area Director at Silk Road Medical, and as Chief Commercial Officer at CAE Healthcare (now Elevate Healthcare). Earlier in her career, Ms. Kennedy held commercial positions of increasing responsibility at several healthcare companies, including Cordis, Biomet, Guidant Corporation (now Boston Scientific), and Angiodynamics. She earned a BA in Communications Studies from Northern Illinois University. Anuncio • Jul 24
Inspiremd, Inc. Receives Notice of Non-Compliance with Nasdaq Listing Rule InspireMD, Inc. (the “Company”), on July 17, 2026, received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market. The Notice stated that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days from June 3, 2026 through July 16, 2026, the Company no longer satisfies the minimum bid price requirement. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on The Nasdaq Capital Market under the symbol “NSPR.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a compliance period of 180 calendar days, or until January 13, 2027, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the compliance period. Nasdaq may, in its discretion, require the Company to satisfy the minimum bid price requirement for a period in excess of ten consecutive business days before determining that the Company has demonstrated an ability to maintain long-term compliance. If the Company does not regain compliance by January 13, 2027, the Company may be eligible for an additional 180-calendar-day compliance period, provided that it satisfies the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum bid price requirement, and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, including, if necessary, by effecting a reverse stock split. If the Company is not eligible for an additional compliance period, or otherwise does not appear capable of curing the deficiency, Nasdaq may provide notice that the Company’s common stock will be subject to delisting. In that event, the Company would have the opportunity to appeal Nasdaq’s determination to a Nasdaq Hearings Panel. The Company intends to actively monitor the closing bid price of its common stock and evaluate available options to regain compliance with the minimum bid price requirement, including, if necessary, effecting a reverse stock split. There can be no assurance that the Company will regain compliance with Nasdaq Listing Rule 5550(a)(2) during the initial compliance period or any additional compliance period, or that the Company will otherwise maintain compliance with the other Nasdaq listing requirements. Anuncio • Jul 03
InspireMD, Inc. Announces Resignation of Raymond W. Cohen from Board and Committees, Effective July 1, 2026 InspireMD, Inc. announced that Mr. Raymond W. Cohen, a Class III member of the board of directors, a member of the Audit Committee of the Board and a member of the Compensation Committee of the Board, tendered his resignation from the Board, effective July 1, 2026. Mr. Cohen's resignation from the Board was for personal considerations and not due to any disagreement with the Company, the Board or the management of the Company on any matter relating to the Company's operations, policies, practices or otherwise. The Nominating and Corporate Governance Committee of the Board intends to identify and evaluate suitable candidates to fill the vacancy created by Mr. Cohen's resignation. Anuncio • Jun 09
Inspiremd Enrolls First Patient in Cguardians Iii Pivotal Study of Switchguard Neuro Protection System for Use in Tcar Procedures InspireMD, Inc. announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization procedures. The patient was enrolled at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio. CGUARDIANS III is a prospective, multi-center, single-arm, pivotal study that will enroll approximately 103 subjects. The objective of the study is to evaluate the safety and efficacy of the SwitchGuard NPS in providing cerebral embolic protection during TCAR procedures using the CGuard Prime 80 cm stent system for the treatment of carotid artery stenosis in patients at high risk for complications from carotid endarterectomy. Recent Insider Transactions • May 11
Insider recently bought US$106k worth of stock On the 7th of May, Gary Roubin bought around 90k shares on-market at roughly US$1.18 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$186k more in shares than they have sold in the last 12 months. Reported Earnings • May 06
First quarter 2026 earnings released: US$0.16 loss per share (vs US$0.22 loss in 1Q 2025) First quarter 2026 results: US$0.16 loss per share. Revenue: US$3.40m (up 122% from 1Q 2025). Net loss: US$13.7m (loss widened 23% from 1Q 2025). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Anuncio • Apr 28
InspireMD, Inc. to Report Q1, 2026 Results on May 04, 2026 InspireMD, Inc. announced that they will report Q1, 2026 results on May 04, 2026 Anuncio • Apr 13
InspireMD, Inc., Annual General Meeting, Jun 03, 2026 InspireMD, Inc., Annual General Meeting, Jun 03, 2026. Location: 4 menorat hamaor st., tel-aviv., Israel Anuncio • Apr 04
InspireMD, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. InspireMD, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Reported Earnings • Mar 18
Full year 2025 earnings released: US$0.76 loss per share (vs US$0.76 loss in FY 2024) Full year 2025 results: US$0.76 loss per share. Revenue: US$8.98m (up 28% from FY 2024). Net loss: US$48.8m (loss widened 52% from FY 2024). Revenue is forecast to grow 56% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Anuncio • Mar 18
InspireMD, Inc. Provides Earnings Guidance for the Full Year 2026 InspireMD, Inc. provided earnings guidance for the full year 2026. For the year, management currently expects revenue for the full year 2026 to be in the range of $13 million to $15 million, reflecting expected revenue growth of approximately 45% to 65% over 2025. Anuncio • Mar 09
InspireMD, Inc. to Report Q4, 2025 Results on Mar 18, 2026 InspireMD, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Mar 18, 2026 New Risk • Feb 03
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$99k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Minor Risks Significant insider selling over the past 3 months (US$99k sold). Market cap is less than US$100m (US$69.1m market cap). Price Target Changed • Feb 02
Price target increased by 15% to US$5.00 Up from US$4.35, the current price target is an average from 3 analysts. New target price is 207% above last closing price of US$1.63. Stock is down 35% over the past year. The company posted a net loss per share of US$0.76 last year. Anuncio • Dec 20
InspireMD, Inc. Announces Resignation of Kathryn Arnold from Board of Directors and Board Committees, Effective December 31, 2025 InspireMD, Inc. announced that Kathryn Arnold, a Class III member of the board of directors, a member of the compensation committee of the Board, the nominating and corporate governance committee of the Board, and the research and development committee of the Board, tendered her resignation from the Board, effective December 31, 2025. Ms. Arnold's resignation from the Board was not due to any disagreement with the Company, the Board or the management of the Company on any matter relating to the Company's operations, policies, practices or otherwise. Anuncio • Nov 05
Inspiremd, Inc. Provides Revenue Guidance for the Fourth Quarter of 2025 InspireMD, Inc. provided revenue guidance for the fourth quarter of 2025. For the fourth quarter, the company expects sequential growth in U.S. sales and steady demand trends internationally, resulting in revenue of approximately $2.5 million to $3.0 million in the fourth quarter. Reported Earnings • Nov 04
Third quarter 2025 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2024) Third quarter 2025 results: US$0.17 loss per share (further deteriorated from US$0.16 loss in 3Q 2024). Revenue: US$2.52m (up 39% from 3Q 2024). Net loss: US$12.7m (loss widened 61% from 3Q 2024). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Anuncio • Nov 04
InspireMD, Inc. Appoints Peter A. Soukas, M.D., as Chief Medical Officer InspireMD, Inc. announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention. Dr. Soukas brings significant experience and credentials in the field of vascular intervention to InspireMD. He serves as the Director of Vascular Medicine and the Peripheral Vascular Interventional Laboratory at The Miriam Hospital and is an Associate Professor of Medicine at The Warren Alpert Medical School of Brown University, where he also directs the Vascular and Endovascular Medicine Fellowship Program, which he founded. He is a Fellow of the American College of Cardiology, the Society of Vascular Medicine, the Society of Coronary Angiography and Interventions, and the American College of Physicians. In addition to his role at InspireMD, Dr. Soukas will be maintaining his clinical practice. Dr. Soukas’ clinical expertise and leadership in the interventional community speaks volumes for his passion and commitment to improving patient outcomes and advancing technology and innovation. He has served as the site principal investigator on more than 24 trials in carotid stenting, the site principal investigator on more than 150 endovascular trials, is a highly sought-after speaker having delivered over 300 invited lectures, and is a prolific researcher, publishing dozens of peer-reviewed papers with deep relationships among other key opinion leaders who shape the field. He is board certified in cardiovascular disease, interventional cardiology, vascular medicine, and endovascular medicine, and is certified in noninvasive vascular lab interpretation. Anuncio • Oct 22
InspireMD, Inc. to Report Q3, 2025 Results on Nov 04, 2025 InspireMD, Inc. announced that they will report Q3, 2025 results on Nov 04, 2025 Anuncio • Sep 18
InspireMD, Inc. Announces Resignation of Thomas J. Kester, A Class III Member of the Board of Directors, Member of the Compensation Committee, and the Chairman of the Audit Committee of the Board, Effective September 16, 2025 On September 13, 2025, Mr. Thomas J. Kester, a Class III member of the board of directors of InspireMD, Inc., a member of the compensation committee of the Board (the “Compensation Committee”), and the chairman of the audit committee of the Board, tendered his resignation from the Board, effective September 16, 2025. Mr. Kester’s resignation from the Board was not due to any disagreement with the Company, the Board or the management of the Company on any matter relating to the Company’s operations, policies, practices or otherwise. Anuncio • Sep 17
Inspiremd, Inc. Announces Appointment of Dan Dearen to Board of Directors, Chairman of the Audit Committee and A Member of the Compensation Committee, Effective September 16, 2025 On September 16, 2025, InspireMD, Inc. announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. Mr. Dearen previously served as President, co-Founder, and Chief Financial Officer of Axonics, Inc., During his tenure, Axonics went public and became one of the fastest-growing companies in the medical device sector, helping over 300,000 patients find relief from bladder and bowel dysfunction. Axonics, Inc. was acquired by Boston Scientific in November 2024 for $3.7 billion. Until July 2024, Mr. Dearen also served as Chair of the Audit Committee and a Board member at Endotronix, a medical device company leveraging pulmonary artery (PA) pressure and vital sign data to improve care for patients with heart failure. He currently holds the same roles at JenaValve Technology, a developer of innovative transcatheter heart valve (THV) solutions, and BetaBionics, the creator of the iLet Bionic Pancreas, an autonomous insulin delivery system that determines every insulin dose for patients with diabetes. Prior to co-founding Axonics, Mr. Dearen held the role of Chief Operating and Financial Officer at Vessix Vascular, a medical device company focused on hypertension therapies, which Boston Scientific acquired in 2012 for $425 million. Mr. Dearen received his B.B.A. in Accounting and Business from Southern Methodist University and his M.B.A. from Boston College. Mr. Dearen’s appointment to the Board of Directors follows the appointment of Mr. Ray Cohen, announced in July 2025. In connection with his appointment, Mr. Dearen was also appointed as the chairman of the Audit Committee and a member of the Compensation Committee. Anuncio • Sep 09
InspireMD, Inc. Appoints Raymond W. Cohen to Serve as A Member of the Audit Committee and the Compensation Committee of the Board, Effective September 7, 2025 On September 7, 2025, the Board of InspireMD, Inc. appointed Mr. Raymond W. Cohen to serve as a member of the Audit Committee and the Compensation Committee of the Board. New Risk • Aug 06
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Reported Earnings • Aug 05
Second quarter 2025 earnings released: US$0.26 loss per share (vs US$0.22 loss in 2Q 2024) Second quarter 2025 results: US$0.26 loss per share (further deteriorated from US$0.22 loss in 2Q 2024). Revenue: US$1.78m (up 2.2% from 2Q 2024). Net loss: US$13.2m (loss widened 66% from 2Q 2024). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Anuncio • Jul 31
Inspiremd Announces Appointment of Raymond W. Cohen to Its Board of Directors InspireMD, Inc. announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. Mr. Cohen was the CEO and co-founder of Axonics, Inc., which he took public in late 2018 and led through its $3.7 billion acquisition by Boston Scientific in November 2024. Axonics earned recognition as the number one fastest-growing company in the Americas by Deloitte and the Financial Times in 2021. Until May of 2025, Mr. Cohen served as Chairman of SoniVie Ltd., a clinical stage company focused on a device treatment for hypertension until it was acquired by Boston Scientific for $600 million. Cohen also serves as an independent director for Kestra Medical (Nasdaq: KMTS) and PE-backed Spectrum Vascular Inc., as well as Chairman of privately held Nalu Medical and Vice Chairman of privately held Tulavi, Inc. Previously, Cohen was CEO of Vessix Vascular, Inc., and publicly traded Cardiac Science Inc., a pioneer in automated external defibrillators which was later acquired by Zoll Medical. Mr. Cohen’s work has earned him numerous honors, including the MedTech MVP Award, EY Entrepreneur of the Year, and a Lifetime Achievement Award from SoCalBio. Anuncio • Jul 22
InspireMD, Inc. to Report Q2, 2025 Results on Aug 05, 2025 InspireMD, Inc. announced that they will report Q2, 2025 results on Aug 05, 2025 Anuncio • Jun 25
InspireMD, Inc. Announces FDA Approval for CGuard®? Prime Carotid Stent System for the Prevention of Stroke InspireMD, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted premarket application (PMA) approval of the CGuard Prime Carotid Stent System in the United States. The PMA approval is backed by best-in-class evidence from the Company's C-GUARDIANS pivotal trial, first presented at the Leipzig Interventional Course (LINC) in May 2024. CGuard Prime demonstrated the lowest 30-day (0.95%) and 1-year (1.93%) primary endpoint major adverse event rates of any pivotal study of carotid intervention. The Company's announcement of FDA approval of the CGuard Prime carotid Stent System triggers the second of four milestone-driven warrant tranches pursuant to the private placement financing of up to $113.6 million announced in May 2023. Proceeds, if any, will be used to support the imminent commercial launch of the CGuard Prime CarOTid Stent System in theUnited States, initiating new regulatory pathways for advanced applications of CGuard stent platform, and developing new products, while at the same time continuing to develop business outside of the United States. Anuncio • Jun 04
InspireMD, Inc. Appoints Michael Lawless as Chief Financial Officer, Effective on or Prior to June 30, 2025 InspireMD, Inc. announced the appointment of Michael Lawless, an industry veteran, as Chief Financial Officer, effective on or prior to June 30, 2025 (the “Effective Date”). On the Effective Date, Mr. Lawless will succeed Craig Shore, who has served as Chief Financial Officer of InspireMD for nearly 15 years.Mr. Lawless is an experienced public company CFO with decades of financial leadership throughout the healthcare space. For the past three years, he has served as CFO of Lifeward (formerly ReWalk Robotics). Previously, he served as the CFO of the $200 million Life Sciences unit of Brooks Automation. Mr. Lawless also served in several other senior corporate finance roles. Reported Earnings • May 10
First quarter 2025 earnings released: US$0.22 loss per share (vs US$0.20 loss in 1Q 2024) First quarter 2025 results: US$0.22 loss per share (further deteriorated from US$0.20 loss in 1Q 2024). Revenue: US$1.53m (up 1.2% from 1Q 2024). Net loss: US$11.2m (loss widened 59% from 1Q 2024). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. New Risk • Apr 25
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$79.7m market cap). Anuncio • Apr 25
InspireMD, Inc. to Report Q1, 2025 Results on May 09, 2025 InspireMD, Inc. announced that they will report Q1, 2025 results on May 09, 2025 Anuncio • Apr 16
InspireMD, Inc., Annual General Meeting, Jun 03, 2025 InspireMD, Inc., Annual General Meeting, Jun 03, 2025. Location: te offices of inspiremd , 4 menorat hamaor st., tel-aviv, israel United States Anuncio • Apr 02
InspireMD, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. InspireMD, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering New Risk • Mar 13
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (US$83.4m market cap). Reported Earnings • Mar 12
Full year 2024 earnings released: US$0.76 loss per share (vs US$0.82 loss in FY 2023) Full year 2024 results: US$0.76 loss per share. Revenue: US$7.01m (up 13% from FY 2023). Net loss: US$32.0m (loss widened 61% from FY 2023). Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Medical Equipment industry in the US. Anuncio • Feb 26
InspireMD, Inc. to Report Q4, 2024 Results on Mar 12, 2025 InspireMD, Inc. announced that they will report Q4, 2024 results on Mar 12, 2025 Anuncio • Dec 12
Craig Shore Decides to Retire as Chief Financial Officer of InspireMD, Inc InspireMD, Inc. announced that Craig Shore, Chief Financial Officer, has decided to retire from the Company after a successor CFO is identified and appointed. Mr. Shore will remain as CFO until his successor is appointed and will assist in a smooth and orderly transition. Price Target Changed • Dec 11
Price target increased by 9.2% to US$4.75 Up from US$4.35, the current price target is an average from 2 analysts. New target price is 50% above last closing price of US$3.17. Stock is up 37% over the past year. The company posted a net loss per share of US$0.82 last year. Anuncio • Dec 10
Inspiremd Announces First Patient Enrolled in the Cguardians Ii Pivotal Study of the Cguard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures InspireMD, Inc. announced that the first patient has been enrolled in the company’s CGUARDIANS II clinical trial evaluating its CGuard Prime Carotid Stent System in patients undergoing carotid artery stenting via the Transcarotid Artery Revascularization (TCAR) approach. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio. Dr. Muck serves as both the site principal investigator as well as a co-lead investigator of the CGUARDIANS II study. CGUARDIANS II is a prospective, multi-center, single arm pivotal study that aims to enroll a minimum of 50 evaluable patients. The objective of this study is to evaluate acute device success and technical success of the CGuard Prime when used in conjunction with an FDA-cleared TCAR neuro-protection system in patients at high risk for adverse events from carotid endarterectomy. Anuncio • Nov 26
InspireMD, Inc. Appoints Scott R. Ward to Its Board of Directors InspireMD, Inc. announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023. Mr. Ward has over 40 years of experience in the healthcare industry, including nearly 30 years at Medtronic, Inc. where he served in various leadership roles including as Senior Vice President and President of the CardioVascular, Neurological and Diabetes businesses. Mr. Ward is the Founder of Raymond Holdings, a firm with activities in venture capital, strategy and transactional advisory services for medical technology and life science companies. He earned his Bachelor of Science in Genetics and Cell Biology, his Master of Science in Toxicology, and his Master of Business Administration, all from the University of Minnesota. Reported Earnings • Nov 13
Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023) Third quarter 2024 results: US$0.16 loss per share (further deteriorated from US$0.15 loss in 3Q 2023). Revenue: US$1.81m (up 16% from 3Q 2023). Net loss: US$7.89m (loss widened 52% from 3Q 2023). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Anuncio • Nov 04
InspireMD, Inc. to Report Q3, 2024 Results on Nov 12, 2024 InspireMD, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 12, 2024 Anuncio • Oct 07
InspireMD, Inc. Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System InspireMD, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) Application to initiate the CGUARDIANS II pivotal study of its CGuard Prime 80cm Carotid Stent System during transcarotid revascularization (TCAR) procedures. In February 2024, InspireMD announced that Patrick Geraghty, M.D., professor of surgery and radiology, section of vascular surgery at Washington University School of Medicine in St. Louis, MO, and Patrick Muck, M.D., program director and chief of vascular surgery at Good Samaritan Hospital in Cincinnati, OH, have agreed to act as lead investigators for the trial. Anuncio • Sep 16
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System InspireMD, Inc. announced that it has submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) seeking marketing approval for the CGuard Prime carotid stent system in the U.S. The PMA application is based on the overwhelmingly positive one-year data from the Company's C-GUARDIANS pivotal clinical trial that were presented at the Leipzig Interventional Course (LINC) 2024 in May. The C-GUARDIANS clinical trial evaluated the safety and efficacy of CGuard for the treatment of carotid artery stenosis. The study enrolled 316 patients across 24 trial sites in the U.S. and Europe. The C-GUARDIANS results showed a primary endpoint1 major adverse event rate of 1.95% through twelve months post-procedure, the lowest such event rate reported for any carotid stent or embolic protection device pivotal trial to date. Reported Earnings • Aug 06
Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2023) Second quarter 2024 results: US$0.22 loss per share. Revenue: US$1.74m (up 5.5% from 2Q 2023). Net loss: US$7.91m (loss widened 56% from 2Q 2023). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. New Risk • Jul 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (US$82.9m market cap). Anuncio • Jul 30
InspireMD, Inc. to Report Q2, 2024 Results on Aug 06, 2024 InspireMD, Inc. announced that they will report Q2, 2024 results on Aug 06, 2024 Recent Insider Transactions Derivative • Jun 28
Independent Director exercised options to buy US$153k worth of stock. On the 24th of June, Michael Berman exercised options to buy 61k shares at a strike price of around US$1.38, costing a total of US$85k. This transaction amounted to 17% of their direct individual holding at the time of the trade. Since September 2023, Michael's direct individual holding has decreased from 318.62k shares to 127.88k. Company insiders have collectively bought US$296k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • May 15
First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023) First quarter 2024 results: US$0.20 loss per share. Revenue: US$1.51m (up 22% from 1Q 2023). Net loss: US$7.03m (loss widened 65% from 1Q 2023). Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Anuncio • May 09
InspireMD, Inc. to Report Q1, 2024 Results on May 14, 2024 InspireMD, Inc. announced that they will report Q1, 2024 results Pre-Market on May 14, 2024 Board Change • May 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Chair of Scientific Advisory Board Ken Rosenfield was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Anuncio • Apr 20
InspireMD, Inc., Annual General Meeting, Jun 10, 2024 InspireMD, Inc., Annual General Meeting, Jun 10, 2024, at 10:00 US Eastern Standard Time. Location: 4 Menorat Hamaor St. Tel-Aviv Israel Agenda: To consider the election of two Class 1 directors to serve on board of directors for a term of three years or until his or her successor is elected and qualified, for which Paul Stuka and Gary Roubin are the nominees; to approve the Company's executive compensation; to approve the frequency of future advisory votes on the Company's executive compensation; to consider the ratification of the appointment of Kesselman & Kesselman, Certified Public Accountants, a member of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the year ending December 31, 2024; and to consider such other business as may properly come before the Annual Meeting. Major Estimate Revision • Mar 12
Consensus revenue estimates decrease by 12%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$7.97m to US$7.05m. EPS estimate increased from -US$0.78 to -US$0.76 per share. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$4.85 unchanged from last update. Share price fell 6.5% to US$2.46 over the past week. Reported Earnings • Mar 06
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: US$0.82 loss per share. Revenue: US$6.21m (up 20% from FY 2022). Net loss: US$19.9m (loss widened 7.7% from FY 2022). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates by 5.7%. Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Anuncio • Feb 29
InspireMD, Inc. to Report Q4, 2023 Results on Mar 06, 2024 InspireMD, Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 06, 2024 Recent Insider Transactions • Dec 05
Insider recently bought US$127k worth of stock On the 30th of November, Gary Roubin bought around 50k shares on-market at roughly US$2.53 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Major Estimate Revision • Nov 13
Consensus EPS estimates fall by 13% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.77 to -US$0.87 per share. Revenue forecast unchanged at US$6.10m. Medical Equipment industry in the US expected to see average net income growth of 25% next year. Consensus price target of US$4.85 unchanged from last update. Share price fell 6.0% to US$3.14 over the past week. Price Target Changed • Nov 02
Price target increased by 18% to US$4.85 Up from US$4.13, the current price target is an average from 2 analysts. New target price is 45% above last closing price of US$3.34. Stock is up 201% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$2.35 last year. Anuncio • Nov 02
Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption (Ide) Clinical Trial InspireMD, Inc. presented 30-day results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial at the Vascular InterVentional Advances (VIVA) meeting, which is being held October 30 through November 2 in Las Vegas, NV. The presentation, which was accepted as a late-breaking abstract, was delivered by Dr. Chris Metzger, System Vascular Chief at OhioHealth in Columbus, OH and principal investigator of the C-GUARDIans trial. The company believe the neuroprotective qualities of C-Guard set it apart from competing stents on the market and should help accelerate the ongoing shift in carotid revascularizations from 'surgery first' to an endovascular 'stent first' approach. InspireMD anticipates reporting primary endpoint results from C-GUARDIANS in the second half of 2024 that may support a Premarket Approval (PMA) application. Anuncio • Oct 31
InspireMD, Inc. to Report Q3, 2023 Results on Nov 06, 2023 InspireMD, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 06, 2023 Anuncio • Oct 05
InspireMD, Inc. Announces Management Appointments InspireMD, Inc. announced senior leadership additions and changes intended to support the company’s commercial growth initiatives, including potential approval of the CGuard Prime stent platform in the U.S., development of new stent delivery systems, and growth in existing approved territories outside of the U.S. The company announced that it has hired Patrick Verta, MD, as Executive Vice President of Clinical and Medical Affairs. In addition, Shane Gleason, who previously served as InspireMD’s General Manager of North America and VP of Global Marketing, has been promoted to Chief Commercial Officer. Dr. Patrick Verta joins InspireMD from Canary Medical, a developer of implantable remote patient monitoring sensor technology and complementary data and analytics, where he served as Chief Medical Officer. Prior to that, he was Founder and Chief Executive Officer of Axelmed LLC, a consultancy focused on strategy and clinical, scientific, medical, and regulatory affairs for medical device companies. Before Axelmed, he spent the prior five years in various roles at Edwards Lifesciences, most recently as VP of Global Medical Affairs, Clinical Science and Biometrics in the Transcatheter Mitral and Tricuspid Therapies (TMTT) division. Earlier in his career, he held senior leadership positions at Sunshine Heart, Neomend, Abbott Vascular (part of Abbott) and Guidant (acquired by Abbott), among others. Dr. Verta received his Doctor of Medicine (M.D.) from Faculté de Médecine in Paris. Major Estimate Revision • Aug 14
Consensus EPS estimates upgraded to US$0.77 loss The consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -US$1.37 to -US$0.77 per share. Revenue forecast steady at US$6.07m. Medical Equipment industry in the US expected to see average net income growth of 23% next year. Consensus price target up from US$4.13 to US$4.35. Share price rose 3.5% to US$3.21 over the past week. Price Target Changed • Aug 09
Price target increased by 12% to US$4.35 Up from US$3.88, the current price target is an average from 2 analysts. New target price is 40% above last closing price of US$3.10. Stock is up 61% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$2.35 last year. Reported Earnings • Aug 08
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Second quarter 2023 results: US$0.24 loss per share. Revenue: US$1.65m (up 7.7% from 2Q 2022). Net loss: US$5.08m (loss widened 9.5% from 2Q 2022). Revenue exceeded analyst estimates by 6.7%. Earnings per share (EPS) also surpassed analyst estimates by 44%. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Anuncio • Jul 29
InspireMD, Inc., Annual General Meeting, Sep 13, 2023 InspireMD, Inc., Annual General Meeting, Sep 13, 2023, at 10:00 US Eastern Standard Time. Location: 4 Menorat Hamaor St. Tel-Aviv Israel Agenda: T consider the election of three Class 3 directors to serve on board of directors for a term of three years or until his or her successor is elected and qualified, for which Marvin Slosman, Thomas J. Kester and Kathryn Arnold are the nominees; to approve the potential issuance of shares in the Private Placement Offering; to approve an amendment to Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law; to consider the ratification of the appointment of Kesselman & Kesselman, Certified Public Accountants, a member of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the year ending December 31, 2023; and to consider such other business as may properly come before the Annual Meeting. Anuncio • Jul 26
InspireMD, Inc. to Report Q2, 2023 Results on Aug 08, 2023 InspireMD, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 08, 2023 Anuncio • Jun 28
InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical Trial InspireMD, Inc. announced that it completed enrollment of its ongoing C-Guardians U.S. Investigational Device Exemption (IDE) clinical trial, designed to support potential U.S. marketing approval of the CGuard Prime EPS stent system. The C-Guardians clinical trial is evaluating the safety and efficacy of the CGuard™ Carotid Stent System for the treatment of carotid artery stenosis. The study, which commenced enrollment in July 2021, enrolled 315 patients across 25 trial sites in the U.S. and Europe. The trial includes both symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS). The primary endpoint includes the composite of the following: incidence of the following major adverse events: death (all- cause mortality), all stroke, and myocardial infarction (DSMI) through 30-days post-index procedure, based on the Clinical Events Committee (CEC) adjudication or ipsilateral stroke from 31-365-day follow-up, based on CEC adjudication. The performance goal will be considered to have been met if the upper bound of the two-sided 95% confidence interval calculated from the observed primary endpoint rate is <11.6% and the p-value is <0.025. The company anticipates results from the study in second half 2024. Major Estimate Revision • May 19
Consensus estimates of losses per share improve by 46% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from US$5.70m to US$5.90m. EPS estimate increased from -US$2.56 per share to -US$1.37 per share. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target down from US$5.15 to US$4.75. Share price rose 23% to US$1.70 over the past week. Anuncio • May 17
InspireMD, Inc. announced that it has received $42.169643 million in funding from Marshall Wace LLP, OrbiMed Advisors LLC, Nantahala Capital Management, LLC, Soleus Capital Management, L.P., Velan Inc. and other investors On May 16, 2023, InspireMD, Inc. closed the transaction. Anuncio • May 06
InspireMD, Inc. to Report Q1, 2023 Results on May 15, 2023 InspireMD, Inc. announced that they will report Q1, 2023 results on May 15, 2023 Major Estimate Revision • Apr 02
Consensus revenue estimates decrease by 37%, EPS upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$9.00m to US$5.70m. EPS estimate increased from -US$2.61 to -US$2.56 per share. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target down from US$5.60 to US$5.15. Share price rose 3.7% to US$1.13 over the past week. Price Target Changed • Nov 16
Price target decreased to US$5.60 Down from US$16.50, the current price target is provided by 1 analyst. New target price is 454% above last closing price of US$1.01. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$2.59 next year compared to a net loss per share of US$2.03 last year. Reported Earnings • Nov 10
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: US$0.58 loss per share (further deteriorated from US$0.53 loss in 3Q 2021). Revenue: US$1.43m (up 34% from 3Q 2021). Net loss: US$4.53m (loss widened 11% from 3Q 2021). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 48% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 128% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Aug 23
Insider recently bought US$68k worth of stock On the 18th of August, Gary Roubin bought around 36k shares on-market at roughly US$1.91 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$311k more in shares than they have sold in the last 12 months. Reported Earnings • Aug 10
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Second quarter 2022 results: US$0.59 loss per share (down from US$0.46 loss in 2Q 2021). Revenue: US$1.53m (up 48% from 2Q 2021). Net loss: US$4.64m (loss widened 32% from 2Q 2021). Revenue exceeded analyst estimates by 28%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Over the next year, revenue is forecast to grow 37%, compared to a 6.2% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 125% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. Reported Earnings • May 12
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2022 results: US$0.57 loss per share (down from US$0.53 loss in 1Q 2021). Revenue: US$1.18m (up 18% from 1Q 2021). Net loss: US$4.48m (loss widened 38% from 1Q 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 29%. Over the next year, revenue is forecast to grow 50%, compared to a 8.8% growth forecast for the industry in the US. Price Target Changed • Apr 27
Price target decreased to US$9.00 Down from US$16.50, the current price target is provided by 1 analyst. New target price is 250% above last closing price of US$2.57. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$3.20 next year compared to a net loss per share of US$2.03 last year. Reported Earnings • Mar 10
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: US$2.03 loss per share (up from US$6.97 loss in FY 2020). Revenue: US$4.50m (up 81% from FY 2020). Net loss: US$14.9m (loss widened 42% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 31%, compared to a 11% growth forecast for the industry in the US. Recent Insider Transactions • Jan 01
Insider recently bought US$50k worth of stock On the 28th of December, Gary Roubin bought around 16k shares on-market at roughly US$3.08 per share. In the last 3 months, they made an even bigger purchase worth US$100k. Insiders have collectively bought US$244k more in shares than they have sold in the last 12 months. Recent Insider Transactions • Nov 19
Insider recently bought US$100k worth of stock On the 17th of November, Gary Roubin bought around 26k shares on-market at roughly US$3.86 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$193k more in shares than they have sold in the last 12 months. Reported Earnings • Nov 11
Third quarter 2021 earnings released: US$0.53 loss per share (vs US$0.96 loss in 3Q 2020) The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$1.07m (up 9.3% from 3Q 2020). Net loss: US$4.07m (loss widened 82% from 3Q 2020). Recent Insider Transactions • Aug 28
Insider recently bought US$93k worth of stock On the 25th of August, Gary Roubin bought around 22k shares on-market at roughly US$4.19 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Major Estimate Revision • Aug 17
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$4.90m to US$4.60m. 2021 losses expected to reduce from -US$547 to -US$2.62 per share. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target of US$16.50 unchanged from last update. Share price fell 7.1% to US$3.68 over the past week. Reported Earnings • Aug 12
Second quarter 2021 earnings released: US$0.46 loss per share (vs US$2.93 loss in 2Q 2020) Second quarter 2021 results: Net loss: US$3.51m (loss widened 41% from 2Q 2020). Reported Earnings • May 12
First quarter 2021 earnings released: US$0.53 loss per share (vs US$6.42 loss in 1Q 2020) First quarter 2021 results: Net loss: US$3.24m (loss widened 64% from 1Q 2020). Reported Earnings • Mar 10
Full year 2020 earnings released: US$0.47 loss per share (vs US$4.80 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$2.49m (down 33% from FY 2019). Net loss: US$10.5m (loss widened 5.0% from FY 2019). Over the last 3 years on average, earnings per share has increased by 165% per year but the company’s share price has fallen by 82% per year, which means it is significantly lagging earnings.